Scott Shultz has over 20 years of pharmaceutical development experience at Merck in the process and analytical development areas. Since 2008 Scott has led numerous efforts in the materials science and preformulation areas developing broad expertise in salt/polymorph screening, crystal form selection, establishing relationships between API particle properties and pharmaceutical performance, and crystallization process development. Scott has impacted the development of commercial products including Welireg, Zepatir, Prevymis and Emend in addition to dozens of clinical candidates during his tenure at Merck. Scott received his B.A. in chemistry from Transylvania University in 1996 and completed his Ph.D. in organic and organometallic chemistry at the University of North Carolina at Chapel Hill in 2001.